Interim report April - June 2022
Gothenburg, August 25, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2022.Important events during the second quarter · In April, Vicore announced that the first patient in the clinical investigation of the digital therapeutic (DTx) in IPF was enrolled. · In April, Vicore submitted a clinical trial application (CTA) to start a phase 1 trial with the new drug candidate (C106) from the VP03 program. · In June, Vicore announced an amendment of the primary endpoint to all-cause mortality and a reduced sample size in the phase 3 trial in